Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of action of secukinumab in spondyloarthritis synovial inflammation and tissue remodeling
2013-002709-79Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of secukinumab in spondyloarthritis (SpA) and other inflammatory spondylopathies, sponsored by Academic Medical Center. Started Jan 2014; status: active.
02
Drugs
secukinumab
03
Conditions
spondyloarthritis (SpA)other inflammatory spondylopathies
Beyond the preview
Go deeper on 2013-002709-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002709-79.